Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Earle F Burgess"'
Autor:
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 1-9 (2023)
Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. Objective: To bett
Externí odkaz:
https://doaj.org/article/859488fb49644ff6bbf4afa1b1012ee4
Autor:
Zainab Shahid, Alicia L. Patrick, Michelle L. Wallander, Erin E. Donahue, Sally J. Trufan, Antoinette R. Tan, Jimmy J. Hwang, Earle F. Burgess, Brittany Ragon, Nilanjan Ghosh, Michael R. Grunwald, Peter M. Voorhees, Edward A. Copelan, Derek Raghavan
Publikováno v:
Vaccine: X, Vol 14, Iss , Pp 100289- (2023)
Purpose: Cancer patients are at high risk of developing severe illness from SARS-CoV-2 infection, but risk is lowered with receipt of COVID-19 vaccine. COVID-19 vaccination uptake among previously infected cancer patients may be influenced by an assu
Externí odkaz:
https://doaj.org/article/b5e30d5ae392467681a5ca38f490956d
Autor:
Jason Zhu, Chad Livasy, Erin E. Donahue, James T. Symanowski, Claud M. Grigg, Landon C. Brown, Justin T. Matulay, James T. Kearns, Derek Raghavan, Earle F. Burgess, Peter E. Clark
Publikováno v:
Translational Andrology and Urology. 12:228-240
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e8c09e835ebc0295cb6909b44431e0f
https://doi.org/10.21037/tau-22-494
https://doi.org/10.21037/tau-22-494
Publikováno v:
Holland‐Frei Cancer Medicine. :1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae50aeb49afb8305a38923182a41614
https://doi.org/10.1002/9781119000822.hfcm098.pub2
https://doi.org/10.1002/9781119000822.hfcm098.pub2
Publikováno v:
Holland‐Frei Cancer Medicine. :1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cfdaad7af69836807e3412012920d71
https://doi.org/10.1002/9781119000822.hfcm097.pub2
https://doi.org/10.1002/9781119000822.hfcm097.pub2
Autor:
Emily, Roebuck, Wei, Sha, Caroline D, Lu, Caroline, Miller, Earle F, Burgess, Claud M, Grigg, Jason, Zhu, Kris E, Gaston, Stephen B, Riggs, Justin T, Matulay, Peter E, Clark, James T, Kearns
Publikováno v:
Urology. 163:156-163
To evaluate whether racial disparities in MRI-Bx usage persisted after correction for socioeconomic, demographic, and clinical factors.This is a retrospective cohort study of patients who received either MRI-Bx or systematic biopsy (SB) within a sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30438caa9e33321969ca0f1a585284eb
https://doi.org/10.1016/j.urology.2021.11.040
https://doi.org/10.1016/j.urology.2021.11.040
Autor:
Eddy S. Yang, Susan Halabi, Michael Rothe, Elizabeth Garrett-Mayer, Pam K. Mangat, Evan Pisick, Elie Dib, Earle F. Burgess, Michael Zakem, Nitin Rohatgi, Mehmet A. Bilen, Raegan O'Lone, Gina N. Grantham, Richard L. Schilsky
Publikováno v:
JCO Precision Oncology.
PURPOSE The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d9e250e0ae7b39ca57bb0a8442c548
https://doi.org/10.1200/po.22.00505
https://doi.org/10.1200/po.22.00505
Autor:
James T. Kearns, Jason Zhu, Stephen B. Riggs, Kris E. Gaston, Timothy Hetherington, Claud Grigg, Earle F. Burgess, William E. Anderson, Justin T. Matulay, Peter E. Clark
Publikováno v:
Urology Practice. 8:619-623
Introduction:5-Alpha reductase inhibitor (5-ARI) use leads to a 50% decline in serum prostate specific antigen (PSA) without a concomitant decrease in prostate cancer (PCa) risk. We hypothe...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8df786099986a96516d235e848fe9ce8
https://doi.org/10.1097/upj.0000000000000257
https://doi.org/10.1097/upj.0000000000000257
Autor:
R. Tucker Burks, Cory Brouwer, Justin T. Matulay, Connor Frasier, Aaron Hartman, David M. Foureau, James T. Kearns, Earle F. Burgess, Stephen B. Riggs, Peter E. Clark, Jason Zhu, Claud Grigg, Nury Steuerwald, J. Alexa Sanders, Kris E. Gaston
Publikováno v:
Transl Androl Urol
Background Intravesical bacillus Calmette-Guerin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918105d8e3da4b9dc90ca6be616ce60e
https://doi.org/10.21037/tau-21-158
https://doi.org/10.21037/tau-21-158
Autor:
Derek Raghavan, Jason Zhu, Aaron Hartman, Jiaxian He, Claud Grigg, Peter E. Clark, Chad A. Livasy, Earle F. Burgess
Publikováno v:
Human Pathology. 107:96-103
Summary Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 5–10% of primary urothelial carcinomas (UCs) but has not reliably predicted benefit from HER2-targeted agents in the metastatic setting. HER2 testing of primary tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fd954112eaeae57c844180dd8d50d0
https://doi.org/10.1016/j.humpath.2020.10.006
https://doi.org/10.1016/j.humpath.2020.10.006